Search Results - "Stuart, William H"

Health-related quality of life in multiple sclerosis: effects of natalizumab by Rudick, Richard A., Miller, Deborah, Hass, Steve, Hutchinson, Michael, Calabresi, Peter A., Confavreux, Christian, Galetta, Steven L., Giovannoni, Gavin, Havrdova, Eva, Kappos, Ludwig, Lublin, Fred D., Miller, David H., O'Connor, Paul W., Phillips, J. Theodore, Polman, Chris H., Radue, Ernst-Wilhelm, Stuart, William H., Wajgt, Andrzej, Weinstock-Guttman, Bianca, Wynn, Daniel R., Lynn, Frances, Panzara, Michael A.

“…Objective To report the relationship between disease activity and health‐related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of…”
Get full text

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS by Weinstock-Guttman, Bianca, Galetta, Steven L., Giovannoni, Gavin, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, O’Connor, Paul W., Phillips, J. Theodore, Polman, Chris, Stuart, William H., Lynn, Frances, Hotermans, Christophe

“…Standard clinical endpoints in multiple sclerosis (MS) studies, such as disability progression defined by the expanded disability status scale (EDSS) and…”
Get full text

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities by Stuart, William H.

“…ABSTRACT Objective: Multiple sclerosis (MS) is a complex, heterogeneous disease. Standard treatment of relapsing MS includes interferon beta (IFNβ) and…”
Get full text

Current clinical perspectives on the treatment of multiple sclerosis by STUART, William H

Get full text

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis by Stuart, William H, Cohan, Stanley, Richert, John R, Achiron, Anat

“…Multiple sclerosis (MS) is a complex, incurable disease. Treatment consists of lifelong disease and symptom management. FDA-approved therapies for relapsing MS…”
Get full text

Concomitant therapy for multiple sclerosis by Stuart, William H, Vermersch, Patrick

“…Interferon beta (IFNbeta) is the first-line treatment for patients diagnosed with multiple sclerosis (MS). In patients with MS who experience breakthrough…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, Michael, Kappos, Ludwig, Calabresi, Peter A., Confavreux, Christian, Giovannoni, Gavin, Galetta, Steven L., Havrdova, Eva, Lublin, Fred D., Miller, David H., O’Connor, Paul W., Phillips, J. Theodore, Polman, Chris H., Radue, Ernst-Wilhelm, Rudick, Richard A., Stuart, William H., Wajgt, Andrzej, Weinstock-Guttman, Bianca, Wynn, Daniel R., Lynn, Frances, Panzara, Michael A.

“…The online version of the original article can be found under doi: 10.1007/s00415-009-0093-1…”
Get full text

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data by Cree, Bruce A C, Stuart, William H, Tornatore, Carlo S, Jeffery, Douglas R, Pace, Amy L, Cha, Choon H

“…Patients with multiple sclerosis (MS) who are of African descent experience a more aggressive disease course than patients who are of white race/ethnicity. In…”
Get more information

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis by Rudick, Richard A, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Radue, Ernst-Wilhelm, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…In this randomized trial involving patients with relapsing multiple sclerosis who had had relapses despite treatment with interferon, natalizumab in…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., O’Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A.

“…The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with…”
Get full text

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management by Stuart, William H

“…To summarize the conclusions of an expert panel of neurologists specializing in multiple sclerosis (MS) convened for the purpose of creating a treatment…”
Get full text

Concomitant therapy for multiple sclerosis: Current clinical perspectives on the treatment of multiple sclerosis by STUART, William H, VERMERSCH, Patrick

Get full text

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis: Current clinical perspectives on the treatment of multiple sclerosis by STUART, William H, COHAN, Stanley, RICHERT, John R, ACHIRON, Anat

Get full text

Stepped-care approach to treating MS: a managed care treatment algorithm by Rich, Sheldon R, Coleman, Imelda C, Cook, Richard, Hum, Douglas S, Johnson, Ben, Maves, Terry, Mazanec, William J, Miller, James R, Proveaux, Woodrow J, Rossman, Howard S, Stuart, William H

“…To introduce a model treatment algorithm for use in the managed care setting as a strategy to provide ongoing disease management and long-term care for…”
Get full text

Natalizumab plus interferon beta-la for relapsing multiple sclerosis by RUDICK, Richard A, STUART, William H, PANZARA, Michael A, SANDROCK, Alfred W, CALABRESI, Peter A, CONFAVREUX, Christian, GALETTA, Steven L, RADUE, Ernst-Wilhelm, LUBLIN, Fred D, WEINSTOCK-GUTTMAN, Bianca, WYNN, Daniel R, LYNN, Frances

Get full text

Evaluation of Monovalent Influenza Vaccine in a Retirement Community During the Epidemic of 1965-1966 by Stuart, William H, Dull, H. Bruce, Newton, Ladene H, McQueen, James L, Schiff, Eugene R

“…Monovalent adjuvant and aqueous influenza vaccines were evaluated in a retirement community from 1964 to 1966. In the second year of investigation, an epidemic…”
Get full text

Methylprednisolone, Mycophenolate Mofetil, or Cyclophosphamide as Combination Therapy With Interferon Beta-1a in Patients With Multiple Sclerosis: Retrospective Study by Stuart, William H., English, Jeffrey, Court, Donna, Warth, John D., Yawn, Steven

“…Currently approved disease-modifying therapies for multiple sclerosis (MS) are only partially effective. This study evaluated the efficacy and safety of…”
Get full text

A novel population of B7‐1+ T cells producing intracellular IL‐4 is decreased in patients with multiple sclerosis by Kipp, Bettina, Bar‐Or, Amit, Gausling, Rudolf, Oliveira, Enedina M. L., Fruhan, Scott A., Stuart, William H., Hafler, David A.

“…We identified a novel population of human T cells, studied directly ex vivo, that co‐express surface B7‐1 and intracellular IL‐4. These peripheral blood…”
Get full text

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis by Munschauer, Frederick E., Stuart, William H.

“…Disease-modifying therapies are now available for the treatment of relapsing-remitting multiple sclerosis (RR-MS). These drugs have transformed the management…”
Get full text

Performance characteristics of the right heart bypass preparation by Grodins, Fred S, Stuart, William H, Veenstra, Rodney L

“…1 Department of Physiology, Northwestern University Medical School, Chicago, Illinois In eight dogs under morphine-barbital anesthesia, the right ventricle was…”
Get full text